Как выбрать хирургическую тактику для рака пищеводно-желудочного перехода?

Автор: Seto Yasuyuki, Yamashita Hiroharu

Журнал: Клиническая практика @clinpractice

Рубрика: Дискуссия

Статья в выпуске: 4 т.10, 2019 года.

Бесплатный доступ

Стандартная хирургия для опухолей пищеводно-желудочного соединения, особенно для аденокарциномы, до сих пор остается спорной. Различные способы были предложены и разрешены для опухолей Siewert типа II. Решение об объеме резекции и размере отступов с каждой стороны определяет выбор той или иной операции. Вместе с тем недавно было показано, что приоритетным фактором в выборе способа резекции является длина инвазии для каждой стороны (пищевода и желудка), потому что это определяет частоту и локализацию метастазирования в лимфатические узлы, которые должны быть удалены. При проксимальной гастрэктомии важным фактором является также размер культи желудка.

Еще

Рак эзофагогастрального перехода, хирургическое лечение, гастрэктомия, реконструкция

Короткий адрес: https://sciup.org/143170801

IDR: 143170801   |   DOI: 10.17816/clinpract19064

Список литературы Как выбрать хирургическую тактику для рака пищеводно-желудочного перехода?

  • Wang K, Yang CQ, Duan LP, et al. Changing pattern of adenocarcinoma of the esophagogastric junction in recent 10 years: experience at a large tertiary medical center in China. Tumori. 2012;98(5):568-574. DOI: 10.1700/1190.13196
  • Liu K, Yang K, Zhang W, et al. Changes of esophagogastric junctional adenocarcinoma and gastroesophageal reflux disease among surgical patients during 1988-2012: a single-institution, high-volume experience in China. Ann Surg. 2016;263(1):88-95. DOI: 10.1097/SLA.0000000000001148
  • Hatta W, Tong D, Lee YY, et al. Different time trend and management of esophagogastric junction adenocarcinoma in three Asian countries. Dig Endosc. 2017;29 Suppl 2:18-25. DOI: 10.1111/den.12808
  • Koizumi S, Motoyama S, Iijima K. Is the incidence of esophageal adenocarcinoma increasing in Japan? Trends from the data of a hospital-based registration system in Akita Prefecture, Japan. J Gastroenterol. 2018;53(7):827-833. DOI: 10.1007/s00535-017-1412-4
  • Brown LM, Devesa SS, Chow WH. Incidence of adenocarcinoma of the esophagus among white Americans by sex, stage, and age. J Natl Cancer Inst. 2008;100(16):1184-1187. DOI: 10.1093/jnci/djn211
  • Pohl H, Sirovich B, Welch HG. Esophageal adenocarcinoma incidence: are we reaching the peak? Cancer Epidemiol Biomarkers Prev. 2010;19(6):1468-1470.
  • DOI: 10.1158/1055-9965.EPI-10-0012
  • Buas MF, Vaughan TL. Epidemiology and risk factors for gastroesophageal junction tumors: understanding the rising incidence of this disease. Semin Radiat Oncol. 2013;23(1):3-9.
  • DOI: 10.1016/j.semradonc.2012.09.008
  • Van Laethem JL, Carneiro F, Ducreux M, et al. The multidisciplinary management of gastro-oesophageal junction tumours: European Society of Digestive Oncology (ESDO): expert discussion and report from the 16th ESMO World Congress on Gastrointestinal Cancer, Barcelona. Dig Liver Dis. 2016;48(11):1283-1289.
  • DOI: 10.1016/j.dld.2016.08.112
  • Siewert JR, Hölscher AH, Becker K, Gössner W. [Cardia cancer: attempt at a therapeutically relevant classification (In German)]. Chirurg. 1987;58(1):25-32.
  • Stein HJ, von Rahden BH, Höfler H, Siewert JR. [Carcinoma of the oesophagogastric junction and Barrett's esophagus: an almost clear oncologic model? (In German)]. Chirurg. 2003;74(8):703-708.
  • Mariette C, Piessen G, Briez N, et al. Oesophagogastric junction adenocarcinoma: which therapeutic approach? Lancet Oncol. 2011;12(3):296-305.
  • DOI: 10.1016/s1470-2045(10)70125-x
  • Zheng Z, Cai J, Yin J, et al. Transthoracic versus abdominal-transhiatal resection for treating Siewert type II/III adenocarcinoma of the esophagogastric junction: a meta-analysis. Int J Clin Exp Med. 2015;8(10):17167-17182.
  • Jezerskyte E, van Berge Henegouwen MI, Cuesta MA, Gisbertz SS. Gastro-esophageal junction cancers: what is the best minimally invasive approach? J Thorac Dis. 2017;9(Suppl 8):S751-S760.
  • DOI: 10.21037/jtd.2017.06.56
  • Mariette C, Castel B, Balon JM, et al. Extent of oesophageal resection for adenocarcinoma of the oesophagogastric junction. Eur J Surg Oncol. 2003;29(7):588-593.
  • DOI: 10.1016/s0748-7983(03)00109-4
  • Ito H, Clancy TE, Osteen RT, et al. Adenocarcinoma of the gastric cardia: what is the optimal surgical approach? J Am Coll Surg. 2004;199(6):880-886.
  • DOI: 10.1016/j.jamcollsurg.2004.08.015
  • Barbour AP, Rizk NP, Gonen M, et al. Adenocarcinoma of the gastroesophageal junction: influence of esophageal resection margin and operative approach on outcome. Ann Surg. 2007;246(1):1-8.
  • DOI: 10.1097/01.sla.0000255563.65157.d2
  • Tsujitani S, Okuyama T, Orita H, et al. Margins of resection of the esophagus for gastric cancer with esophageal invasion. Hepatogastroenterology. 1995;42(6):873-877.
  • Bissolati M, Desio M, Rosa F, et al. Risk factor analysis for involvement of resection margins in gastric and esophagogastric junction cancer: an Italian multicenter study. Gastric Cancer. 2017;20(1):70-82.
  • DOI: 10.1007/s10120-015-0589-6
  • Mine S, Sano T, Hiki N, et al. Proximal margin length with transhiatal gastrectomy for Siewert type II and III adenocarcinomas of the oesophagogastric junction. Br J Surg. 2013;100(8):1050-1054.
  • DOI: 10.1002/bjs.9170
  • Casson AG, Darnton SJ, Subramanian S, Hiller L. What is the optimal distal resection margin for esophageal carcinoma? Ann Thorac Surg. 2000;69(1):205-209.
  • DOI: 10.1016/s0003-4975(99)01262-x
  • Avella D, Garcia L, Hartman B, et al. Esophageal extension encountered during transhiatal resection of gastric or gastroesophageal tumors: attaining a negative margin. J Gastrointest Surg. 2009;13(2):368-373.
  • DOI: 10.1007/s11605-008-0579-7
  • Butte JM, Waugh E, Parada H, De La Fuente H. Combined total gastrectomy, total esophagectomy, and D2 lymph node dissection with transverse colonic interposition for adenocarcinoma of the gastroesophageal junction. Surg Today. 2011;41(9):1319-1323.
  • DOI: 10.1007/s00595-010-4412-z
  • Yamashita H, Seto Y, Sano T, et al.; Japanese Gastric Cancer Association and the Japan Esophageal Society. Results of a nation-wide retrospective study of lymphadenectomy for esopha-gogastric junction carcinoma. Gastric Cancer. 2017;20(Suppl 1):69-83.
  • DOI: 10.1007/s10120-016-0663-8
  • Shiozaki A, Itoi H, Ueda Y, et al. The extending range of the tumor is a more suitable predictive risk factor for lymph node metastases than the location of the deepest tumor invasion in distal thoracic esophageal and cardiac cancer. Oncol Rep. 2005;14(1):195-199.
  • Ueda Y, Shiozaki A, Itoi H, et al. The range of tumor extension should have precedence over the location of the deepest tumor center in determining the regional lymph node grouping for widely extending esophageal carcinomas. Jpn J Clin Oncol. 2006;36(12):775-782.
  • DOI: 10.1093/jjco/hyl105
  • Koyanagi K, Kato F, Kanamori J, et al. Clinical significance of esophageal invasion length for the prediction of mediastinal lymph node metastasis in Siewert type II adenocarcinoma: a retrospective single-institution study. Ann Gastroenterol Surg. 2018;2(3):187-196.
  • DOI: 10.1002/ags3.12069
  • Kurokawa Y, Hiki N, Yoshikawa T, et al. Mediastinal lymph node metastasis and recurrence in adenocarcinoma of the esophagogastric junction. Surgery. 2015;157(3):551-555.
  • DOI: 10.1016/j.surg.2014.08.099
  • Yonemura Y, Kojima N, Kawamura T, et al. Treatment results of adenocarcinoma of the gastroesophageal junction. Hepatogastroenterology. 2008;55(82-83):475-481.
  • Mine S, Kurokawa Y, Takeuchi H, et al. Distribution of involved abdominal lymph nodes is correlated with the distance from the esophagogastric junction to the distal end of the tumor in Siewert type II tumors. Eur J Surg Oncol. 2015;41(10):1348-1353.
  • DOI: 10.1016/j.ejso.2015.05.004
  • Sato Y, Katai H, Ito M, et al. Can proximal gastrectomy be justified for advanced adenocarcinoma of the esophagogastric junction? J Gastric Cancer. 2018;18(4):339-347.
  • DOI: 10.5230/jgc.2018.18.e33
  • Inada T, Yoshida M, Ikeda M, et al. Evaluation of QOL after proximal gastrectomy using a newly developed assessment scale (PGSAS-45). World J Surg. 2014;38(12):3152-3162.
  • DOI: 10.1007/s00268-014-2712-y
Еще
Статья научная